<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ATOVAQUONE/PROGUANIL HYDROCHLORIDE</span><br/>(a-to'va-quone/pro'gua-nil)<br/><span class="topboxtradename">Malarone, </span><span class="topboxtradename">Malarone Pediatric<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiprotozoal</span>; <span class="classification">antimalarial</span><br/><b>Prototype: </b> Chloroquine HCl &amp; Metronidazole<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>Atovaquone 250 mg/proguanil HCl 100 mg, atovaquone 62.5 mg/proguanil HCl 25 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Combination of two antimalarial drugs. Atovaquone inhibits the electron transport system in the mitochondria of the malaria
         parasite, thus interfering with nucleic acid and ATP synthesis of the parasite. Proguanil interferes with DNA synthesis of
         the malaria parasite.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Malarone is effective against strains of <i>Plasmodium </i>spp. and <i>P. falciparum</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prevention and treatment of malaria due to <i>P. falciparum,</i> even in chloroquine-resistant areas.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known hypersensitivity to atovaquone or proguanil; pregnancy (category C); severe malaria.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Cerebral malaria, complicated malaria, pulmonary edema; renal failure, renal impairment; lactation; older adults; African
         Americans, Chinese, Japanese; diarrhea, emesis, GI disease; hepatic disease, infection, sunlight (UV) exposure. Use in children
         weighing 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prevention of Malaria</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 tablet q.d. with food starting 12 d before travel to malarial area and continuing for 7 d after return<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>1120 kg</i>, 1 pediatric tablet q.d.; <i>2130 kg</i>, 2 pediatric tablets q.d.; <i>3140 kg</i>, 3 pediatric tablets q.d.; &gt;<i>40 kg</i>, 1 adult tablet q.d. with food starting 12 d before travel to malarial area and continuing for 7 d after return<br/><br/><span class="indicationtitle">Treatment of Malaria</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 4 tablets as a single daily dose times 3 d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>58 kg</i>, 2 pediatric tablets; <i>910 kg</i>, 3 pediatric tablets; <i>1120 kg</i>, 1 adult tablet; <i>2130 kg</i>, 2 adult tablets; <i>3140 kg</i>, 3 adult tablets; &gt;<i>40 kg</i>, 4 adult tablets as a single daily dose times 3 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give at the same time each day with food or a drink containing milk.</li>
<li>Give a repeat dose if vomiting occurs within 1 h after dosing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fever, <span class="speceff-common">myalgia</span>, back pain, asthenia, anorexia. <span class="typehead">Digestive:</span>
<span class="speceff-common">Nausea, abdominal pain, diarrhea,</span> dyspepsia. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache</span>. <span class="typehead">Respiratory:</span> Cough. <span class="typehead">Skin:</span> Pruritus. <span class="typehead">Other:</span> <span class="speceff-life">Anaphylactic reaction.</span>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Rifampin,</b>
<b>rifabutin,</b>
<b>tetracycline</b> may decrease serum levels; <b>metoclopramide</b> may decrease absorption. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span>
<b>Atovaquone (A),</b> Poorly absorbed from GI tract, absorption is improved when taken with a fatty meal; <b>Proguanil (P),</b> Extensively absorbed. <span class="typehead">Duration:</span>
<b>A,</b> 623 wk after a 3-wk course of therapy. <span class="typehead">Distribution:</span>
<b>A,</b> Penetrates poorly into cerebrospinal fluid; &gt;99.9% protein bound; <b>P,</b> 75% protein bound. <span class="typehead">Metabolism:</span>
<b>A,</b> Not metabolized; <b>P,</b> Metabolized by CYP2C19 to cycloguanil. <span class="typehead">Elimination:</span>
<b>A,</b> &gt;94% excreted in feces over 21 d (enterohepatically cycled); <b>P,</b> Primarily excreted in urine. <span class="typehead">Half-Life:</span>
<b>A,</b> 23 d; <b>P,</b> 1221 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor AST and ALT periodically, especially with long-term therapy.</li>
<li>Monitor for S&amp;S of parasitemia in patients receiving tetracycline and in those experiencing diarrhea or vomiting.</li>
<li>
            							Note: Only use metoclopramide to control vomiting if other antiemetics are not available.
            						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take this drug at the same time each day for maximum effectiveness.</li>
<li>
            							Note: Absorption of this drug may be reduced with diarrhea and vomiting. Consult physician if either of these occurs.
            						
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>